ArticleP & T : a peer-reviewed journal for formulary management2013
Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic Constipation.
Article in P & T : a peer-reviewed journal for formulary management, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Patient-Centered Approach in IBS-C Management.Gastroenterology & hepatology · 2025Article
- Raising Expectations in IBS-C Management.Gastroenterology & hepatology · 2025Article
- Oxalate nephropathy precipitated by linaclotide in a high-risk patient.Clinical nephrology. Case studies · 2025Article
- A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.Gastroenterology & hepatology · 2024Article
- Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.Clinical and experimental gastroenterology · 2024Review
- Understanding the Current Approaches in the Management of IBS-C: A Case Study.Gastroenterology & hepatology · 2023Article
- Enteroendocrine cell regulation of the gut-brain axis.Frontiers in neuroscience · 2023Review
- Cyclic peptide drugs approved in the last two decades (2001-2021).RSC chemical biology · 2022Review
- Improving the Gastrointestinal Stability of Linaclotide.Journal of medicinal chemistry · 2021Article
- Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.Expert opinion on therapeutic targets · 2021Review
- Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation.Cureus · 2019Review
- Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion.Cell host & microbe · 2018Article
- Colonic transit time and pressure based on Bernoulli's principle.Clinical and experimental gastroenterology · 2018Article
- Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Frontiers in pharmacology · 2017Review
- Linaclotide pharmacodynamics.P & T : a peer-reviewed journal for formulary management · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation.
Identifiers
23641133PMC3638410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.